Hyperactivity News and Research

RSS

Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today confirmed plans to present data from its completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium (nAChR2009) in Lincolnshire, Illinois on October 15, 2009.

10 Sep 2009

Half of six million major depressive disorder with comorbid panic attack cases go untreated

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in the U.S., out of six million cases of major depressive disorder with comorbid panic attack, three million are untreated. Comorbid mental disorders are influential factors impacting the diagnosis and treatment of mental disorders.

10 Sep 2009

Adverse impact of drinking during pregnancy highlighted by health department

In recognition of Fetal Alcohol Spectrum Disorder Awareness Week, the Pennsylvania Department of Health today reminded women about the serious implications of drinking while pregnant.

9 Sep 2009

Shire receives FDA approval for INTUNIV extended release tablets

Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

4 Sep 2009

Shire's INTUNIV (Guanfacine) approved by the FDA for treatment of Attention-Deficit/Hyperactivity Disorder

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.

4 Sep 2009

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

Brown University neuroscience professor awarded EUREKA grant

Brown University neuroscience professor Gilad Barnea will receive a nearly $1.3 million, four-year federal grant toward development of a method to selectively monitor the activation of each of the five receptors for the neurotransmitter dopamine in the brain.

4 Sep 2009

LearningRx teaches parents on how to improve their kids' attention

September is National Attention Deficit Hyperactivity Disorder (ADHD) Awareness Month. And, more than 60 LearningRx franchisees are showing parents how to increase the three types of attention skills.

4 Sep 2009

CDC recommends routine health examintion for all school-age children

Although school has just begun, it is already exam time for students throughout Wisconsin. That's because in addition to notebook paper and pens, back-to-school preparations should also include routine health exams to make sure students are healthy and ready to learn. These include: a doctor's exam to confirm that all immunizations are up-to-date, a dental exam and a vision exam.

3 Sep 2009

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S. history.

3 Sep 2009

High DHA levels aid in learning and mental development of school children

Getting ready for the start of a new school year traditionally means shopping trips for crisp, new clothes and backpacks bursting with fresh school supplies. But how do you prepare your child mentally and physically for the demands of hectic schedules and endless homework? It's easy for children, be it primary graders or teenagers, to anticipate the beginning of class with both excitement and some anxiety. These stress factors can quickly turn to feelings of being overwhelmed and frustrated as schoolwork and activities intensify.

27 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

American Public University offers “Tips for Teachers” cards free of cost

“Tips for Teachers” cards on key behavioral and student wellness issues are available at no cost to teachers, counselors, principals and other school-based personnel, thanks to a program by American Public University, a member institution of American Public University System, an accredited, online university system that serves more than 50,000 working adults studying worldwide.

20 Aug 2009

Orient Pharma granted commercialization rights for a drug candidate by DURECT

DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR(R) Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder (ADHD).

19 Aug 2009

Shire starts two adult ADHD outreach programs

Shire plc today announced two initiatives reinforcing their commitment to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral disorder that affects an estimated 10 million adults across the country.

18 Aug 2009

Obesity No. 1 concern for children in the United States

Public concern about childhood obesity is on the rise and it continues to outrank all other health problems as the No. 1 concern for children in the United States.

10 Aug 2009

National Institutes of Health develops research plan on Fragile X syndrome and associated disorders

The National Institutes of Health has developed a research plan to advance the understanding of fragile X syndrome and its associated conditions, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency. Fragile X syndrome causes intellectual and developmental disabilities and results from a mutation in a gene on the X chromosome.

20 Jul 2009

New research tool – map of genomic variation for diagnosing and identifying genetic problems

Genetics researchers have unveiled a powerful new resource for scientists and health providers studying human illnesses -- a reference standard of deletions and duplications of DNA found in the human genome. Drawn from over 2,000 healthy persons, the study provides one of the deepest and broadest sets of copy number variations (CNVs) available to date, along with a new research tool for diagnosing and identifying genetic problems in patients.

15 Jul 2009

Placebo effects in caregivers may change behavior of children with ADHD

Stimulant medications, such as Ritalin and Adderall, are the accepted treatment to stem hyperactivity in children with attention deficit-hyperactive disorder (ADHD) and improve their behavior.

29 Jun 2009

ADHD genes found - missing DNA segments may suggest future drug targets

Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD. Many of those genes were already known to be important for learning, behavior, brain function and neurodevelopment, but had not been previously associated with ADHD.

24 Jun 2009